The Central Drugs Standard Control Organization (CDSCO) has issued an alert regarding the theft of multiple drug products from M/s Novo Nordisk during transit. The theft occurred on a route from the Bhiwandi Hub to Nagpur, Raipur, Cuttack, and Kolkata. The products are r-DNA origin injectables that require specific storage at 2°C to 8°C to maintain their quality and ensure patient safety.
The following products and their respective batch numbers were stolen:
- Insulin degludec/Insulin Aspart (Ryzodeg™ FlexTouch®), Batch No. RT6GY96.
- Insulin aspart (Fiasp® Penfill®), Batch No. RR726A8.
- Insulin aspart (Fiasp® FlexTouch®), Batch No. RP5P640.
- Semaglutide Injection (Wegovy® FlexTouch®) at 0.5mg (Batch No. RP5S233), 0.25mg (Batch No. RP5S232), and 1mg (Batch No. RP5S210).
The quality of these products may be compromised if they are not stored under the proper conditions, which could impact patient safety. The matter is currently under police investigation.
Advisory for Healthcare Professionals and Consumers
In response to the theft, the CDSCO has provided the following advisory:
Doctors and Healthcare professionals are urged to carefully prescribe these products and educate patients on how to report any Adverse Drug Reactions (ADRs).
Patients and consumers are advised to be cautious and to only procure these products from authorized sources, ensuring they receive a proper invoice.
Regulatory authorities have been instructed to maintain a strict vigil on the movement of these products in the market and to take necessary action under the provisions of the Drugs & Cosmetics Act, 1940, and its rules.